Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
CNS symptoms common in people taking raltegravir

Approximately 10% of patients taking the antiretroviral drug raltegravir (Isentress) develop central nervous system (CNS) side-effects, research published in the online edition of AIDS shows. The development of CNS

Published
10 October 2012
By
Michael Carter
Diverse factors influence choice of first ART regimen in Swiss study

enofovir/emtricitabine (TDF/FTC) plus efavirenz was by far the most popular first-line antiretroviral therapy (ART) among Swiss HIV Cohort Study (SHCS) members starting treatment from January 2005 through December 2009. An AIDS diagnosis and a higher viral load favored prescription of the second most popular regimen, TDF/FTC plus lopinavir/ritonavir.

Published
09 October 2012
From
International AIDS Society
HIV Deaths Declining for Most, But Not All, Americans

HIV death rates in the United States declined for most groups of people between 1993 and 2007, according to a large new study.

Published
09 October 2012
From
U.S. News & World Report
Starting HIV treatment reduces the risk of serious non-AIDS-related diseases

Serious non-AIDS-defining illnesses are common in people recently diagnosed with HIV, Spanish investigators report in the online edition of AIDS. “Clinicians should be aware that during the initial

Published
09 October 2012
By
Michael Carter
The genetics of HIV-1 resistance

New research has examined the genetic footprint that drug resistance causes in HIV and found compensatory polymorphisms that help the resistant virus to survive.

Published
08 October 2012
From
Science Daily
Could Sangamo's 'functional cure' for HIV disrupt the drug market?

According to Sangamo Biosciences CEO Ed Lanphier, the biotech group’s gene-therapy technology could end up disrupting the broader pharmaceutical market by providing ‘cures’ for diseases caused by certain genetic malfunctions, thereby freeing patients of cumbersome and often expensive drug regimens.

Published
05 October 2012
From
MarketWatch (blog)
Dosing frequency and number of pills don't affect HIV treatment outcomes

Levels of adherence to modern HIV treatment are unaffected by dosing frequency or number of daily pills, Italian investigators report in HIV Medicine. However, people who were taking

Published
04 October 2012
By
Michael Carter
Ugandan President Museveni blames HIV rise in NGOs’ promotion of ‘prostitution, circumcison and condoms’

President Museveni has blamed the increasing HIV/Aids prevalence in Uganda on non-governmental organisations' promotion of condom use, sex work and circumcision.

Published
03 October 2012
From
Key Correspondents
Higher levels of adherence to hepatitis C therapy improve treatment outcomes in people with hepatitis C and HIV

Higher levels of adherence to pegylated interferon and ribavirin are associated with better hepatitis C treatment responses in people with HIV and hepatitis C co-infection, US investigators report

Published
03 October 2012
By
Michael Carter
From today, HIV treatment is free for all who need it in England

The removal of charges for undocumented migrants and non-UK citizens accessing HIV treatment and care in England comes into effect today. From now on, HIV treatment will be

Published
01 October 2012
By
Roger Pebody

Filter by country